AB-836
- Generic Name
- AB-836
Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection
Phase 1
Terminated
- Conditions
- Chronic Hepatitis
- Interventions
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2022-11-21
- Lead Sponsor
- Arbutus Biopharma Corporation
- Target Recruit Count
- 110
- Registration Number
- NCT04775797
- Locations
- 🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇨🇦Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
🇨🇦Toronto Liver Center, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath